RCMT

ANALYST NOTE: RCM TECHNOLOGIES, INC. (RCMT) DATE: 2026-06-19 SUBJECT: Structural Setup Analysis & Business Fundamentals

1. Structural Readiness

• Conservative Entry: $28.35 (Breakout level).
• Current Price: $26.38.
• Extension: -6.9% vs. conservative entry.
• ATR Context: ATR at breakout was 5.2% (High structural quality). Current ATR is 4.7% (High volatility).
• Classification: This is a FORMING coil. It is not invalidated. The price is holding above the $17.74 support level, indicating the structure remains intact. However, because the price ($26.38) has not yet closed above the conservative entry ($28.35), the setup is incomplete. A forming coil represents a partial signal of readiness but is not actionable on its own until the breakout fires.

2. Thesis Layer

• Thesis Status: TACTICAL / Setup-Led.
• Macro Exposure: There is no named secular thesis attached to this name as of 2026-06-19.
• Judgment Criteria: Conviction must be derived strictly from the quality of the structural setup (the forming coil) and the immediate business fundamentals (backlog growth, margin expansion, and liquidity). Do not assign macro themes (e.g., "AI Infrastructure" or "Green Energy") to this setup unless explicitly stated by management in the provided evidence. The case rests on the company's ability to execute its current operational momentum.

3. Business Fundamentals

RCM Technologies, Inc. operates as a diversified professional services firm with three primary segments: Engineering Services, Specialty Healthcare, and Life Sciences/Data & Solutions.

• Engineering Services: The company provides consulting and project solution services, specifically targeting utilities and data center developers. Management reports that the "integrated engineering and EPC model" is gaining momentum as clients seek partners with technical depth for complex projects.
• *Evidence:* In the Q3 2026 earnings transcript (2025-11-06), management noted that "historically, their CapEx spend might be -- have been $2 billion or $3 billion. Now it's at maybe $5 billion or $6 billion. And then some of them are $8 billion to $10 billion are moving up another level."
• Specialty Healthcare: This segment provides long-term and short-term staffing and placement services. It is the largest revenue contributor.
• *Evidence:* As of the fiscal year ended January 3, 2026, Specialty Health Care services accounted for 51.4% of total revenue (E14). The segment reported Time and Material revenue of $47.785 million and Permanent Placement Services of $319,000 for the thirteen weeks ended April 4, 2026 (E13).
• *Pipeline:* Management stated they have "at least 300 nurses in our pipeline that have passed all exams and are ready to come over if we can get them visas" (E4).
• Financial Performance & Backlog:
• *Backlog:* As of the end of October 2025, the company demonstrated a "record 2026 engineering backlog," growing from $21 million in 2025 to just over $70 million in 2026 (E1, E2).
• *Growth:* School revenue for Q3 '25 grew 20.7% year-over-year to $24.4 million (E5). Year-to-date revenue growth was nearly 45%, with gross profit up ~49% and EBITDA up 110% compared to Q3 2024 (E6).
• *Guidance:* Management reiterated expectations that Q4 would yield the "highest quarterly gross profit and our highest adjusted EBITDA in fiscal 2025" (E3).
• Customer Concentration: The company faces moderate concentration risk. During the thirteen weeks ended April 4, 2026, two customers exceeded 10% of consolidated revenue (25.1% and 15.3%) (E10). For the full fiscal year ended January 3, 2026, the top five customers accounted for approximately 51.0% of revenue (E21).
• Liquidity: The company amended its loan agreement in February 2026, increasing the total commitment from $65.0 million to $75.0 million. As of April 4, 2026, availability for additional borrowings was $33.3 million (E11, E12).

4. Archetype and Conviction

• Archetype: Margin Inflector.
• Rationale: The business fits the "Margin Inflector" archetype due to the rapid expansion of EBITDA (up 110% YTD) outpacing revenue growth (up ~45% YTD) and the shift toward higher-margin engineering and EPC projects. The backlog growth from $21M to $70M suggests a structural shift in the revenue mix toward higher-value, complex projects.
• Structural Quality: The ATR at breakout (5.2%) and current ATR (4.7%) fall into the "High" bucket (4–6%). This indicates healthy volatility and structural quality, avoiding the "extreme" (>8%) risk zone associated with severe losers.
• Conviction Stack:
• *Thesis Strength:* Low (Tactical only).
• *Evidence Quality:* High (Strong backlog data, clear margin expansion, liquidity support).
• *Setup Readiness:* Partial (Forming coil, awaiting breakout).
• *Rerating Potential:* Moderate to High, contingent on the successful execution of the engineering backlog and the resolution of visa bottlenecks in the healthcare pipeline.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen: A daily close above the conservative entry of $28.35, confirming the breakout. Continued reporting of backlog growth or margin expansion in subsequent quarters would also strengthen the case.
• Gaps in Evidence:
• Visa Execution: While management cites a pipeline of 300+ nurses, there is no evidence in the provided text regarding the *actual* conversion rate of these candidates into billable revenue or the specific timeline for visa approvals.
• Customer Retention: While customer concentration is disclosed, there is no specific evidence regarding the retention rates of the top 5 customers or the diversification strategy for the next 12 months.
• Valuation Metrics: No specific P/E, EV/EBITDA, or price-to-sales multiples are provided in the evidence block to contextualize the current price of $26.38 relative to historical or peer valuations.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Record 2026 engineering backlog growth from $21M to $70M; EBITDA up 110% YTD vs revenue up 45%; Liquidity availability of $33.3M with increased credit facility. Key risks: High customer concentration with top two customers representing 40.4% of recent revenue; Visa dependency for 300+ nurse pipeline; Forming coil has not yet broken out. Sizing hint: Position size should be reduced relative to a confirmed breakout setup due to the "forming" status and lack of breakout confirmation. Expected path: Management expects continued backlog growth and margin expansion; price likely to consolidate near current levels until a breakout above $28.35 or a retest of support occurs. Expected horizon: 3 to 6 months for structural confirmation or invalidation. Failure mode to watch: A daily close below $17.74, which would invalidate the structural support and the forming coil thesis.